Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

mportant Sutent® (sunitinib malate) Safety Information

Hepatotoxicity has been observed in clinical trials and post-marketing experience.  This hepatotoxicity may be severe, and deaths have been reported.  It is recommended to monitor liver function tests before initiation of treatment, during each cycle of treatment, and as clinically indicated.  Sutent should be interrupted for Grade 3 or 4 drug-related hepatic adverse events and discontinued if there is no resolution.  Sutent should not be restarted if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.

Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on Sutent.

Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed.  Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure.  Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy.  Complete blood counts (CBCs) with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions in GIST and RCC clinical trials were diarrhea, fatigue, asthenia, nausea, mucositis/stomatitis, anorexia, vomiting, hypertension, dyspepsia, abdominal pain, constipation, rash, hand-foot syndrome, skin discoloration, altered taste and bleeding.

For more information on Sutent including full prescribing information please visit www.pfizer.com.

About Aromasin® (exemestane tablets)

Aromasin is the only aromatase inhibitor indicated for sequential therapy in postmenopausal women with
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: ... today announced financial results for the third quarter ... corporate, commercial, regulatory and clinical development updates from ... pleased with the continued momentum and strong performance ... this quarter, especially the XIAFLEX franchise, which more ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... , , MEMPHIS, Tenn. , Jan. 20 ... SN) Orthopaedics business is making available this week more than $2 ... in the treatment of survivors of last week,s earthquake in Haiti ... range of orthopedic surgical resources used to treat bone fractures. , ...
... Fla. , Jan. 20 Roper Industries, ... for the fourth quarter of 2009, ended December 31, 2009 , ... 2010 .  A conference call to discuss these results has been scheduled ... .  The call can be accessed via webcast or by dialing +1 ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 2Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 3
(Date:10/30/2014)... Seattle, WA (PRWEB) October 30, 2014 Sound ... their decision infographic that will assist people any time they ... people discover the right answer by leading them through a ... a resolution to their initial query. , There are many ... or not to use an answering service . This ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Scientists who ... the laboratory say their breakthrough could provide a new ... of stomach diseases. The team used human pluripotent ... cell in the body -- to grow the functional ... bacteria, a major cause of ulcers and stomach ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, ... bad for your health, a new study reports. Previous ... strengthen bones and prevent osteoporosis. These benefits to bone health ... of a healthy diet. But this new study found ... or women from bone fractures, and was linked to an ...
(Date:10/30/2014)... News) -- Eating a low-carb, high-fat diet could help ... new research. A review of five studies ... focuses on foods like bacon, eggs, heavy cream, butter, ... adults whose condition doesn,t improve with medication. "We ... with epilepsy whose seizures are not stopped by medications," ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... (HealthDay News) -- Workers with chronic low back pain can ... approach to care instead of traditional medical care, a new ... burden in developed countries, with 93 percent of the losses ... reason, researchers in the Netherlands tested a new approach among ...
... presented today at the annual meeting of the Radiological Society ... in the body of a human drug courier, known as ... from South America is making its way to Europe through ... of Berne and Institute of Forensic Medicine of Berne in ...
... and bottles of over-the-counter (OTC) medicines for children in the ... and follow, according to a study in the December 1 ... an unacceptable amount of inconsistency in labels and measuring devices ... MD, assistant professor of pediatrics at NYU School of Medicine ...
... able to use medical means to restrict the growth of ... at home? A working group convened to discuss the ethical ... an article in the Hastings Center Report . Personal ... or speak -- accompany the article Growth attenuation is ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
Cached Medicine News:Health News:Workers With Low Back Pain Benefit From Integrated Care 2Health News:CT best at uncovering drug mule payload 2Health News:Instructions on over-the-counter medications for children are found to be confusing 2Health News:Recommendations issued on controversial 'Ashley' procedure for disabled children 2Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: